CimCure is a new generation company founded by its CSO in 2015, as a spin-off of the VU University Medical Center. CimCure focuses on design and development of a novel class of active cancer vaccines.
Diederik Engbersen, MSc
Diederik holds a MSc degree in medicine from Leyden University, Netherlands, and has more than 25 years of experience in the life science industry holding various international and executive positions in strategic marketing, R&D, business development en general management in both established as well as early stage and start up companies.
Prof. Arjan Griffioen, PhD
Arjan holds a PhD in medicine from Utrecht University, Netherlands. He is a key opinion leader in the field of angiogenesis. He was trained as an immunologist and published >250 peer-reviewed scientific publications. He is heading the Angiogenesis Laboratory, is director of the Graduate School of Oncology (OOA) and is Editor-in-Chief of the journal Angiogenesis that he founded.
Else Huijbers, PhD
Else holds a PhD in medicine from the Uppsala University, Sweden. She was trained as a phamacist and has received several major grants from National and European sources. She presented the first proof-of-concept for using conjugate vaccines against the tumor vasculature.
Scientific Advisory Board
Prof. Ada Kruisbeek
Ada was a long-standing researcher at the NIH before becoming Head of the Department of Immunology of the Netherlands Cancer Institute and Professor of Immunology at the Free University of Amsterdam.
Later, she joined Crucell as Sr VP Research, founded DC-Prime and served as their CEO for many years. Currently, Ada is an advisor to DC-Prime and various other companies and foundations.